- Home
- PIII vs NXL Comparison
PIII vs NXL Comparison
Compare PIII & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | NXL |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | 360 | 7 |
| Industry | Medical/Nursing Services | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 8.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PIII | NXL |
|---|---|---|
| Price | $2.82 | $0.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $16.25 | $5.00 |
| AVG Volume (30 Days) | 100.9K | ★ 200.4K |
| Earning Date | 03-26-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $38.28 |
| Revenue Next Year | $14.85 | $185.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.36 |
| 52 Week High | $11.30 | $2.57 |
Technical Indicators
Market Signals| Indicator | PIII | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 52.47 | 33.91 |
| Support Level | $1.52 | $0.37 |
| Resistance Level | $2.85 | $0.62 |
| Average True Range (ATR) | 0.53 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 30.81 | 21.73 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.